Letermovir tablet

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Cytomegalovirus (CMV) InfectionCytomegalovirus DiseaseCytomegalovirus Infection

Phase 2

Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030)

CompletedNCT03940586

Merck Sharp & Dohme LLCCytomegalovirus (CMV) Infection

Start: 2019-08-08End: 2023-08-25Updated: 2024-08-22

Phase 3

MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)

CompletedNCT04129398

Merck Sharp & Dohme LLCCytomegalovirus Disease, Cytomegalovirus Infection

Start: 2019-12-27End: 2022-10-06Updated: 2024-08-21

Related Papers

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study

Antimicrobial Agents and Chemotherapy2025-08-181 citations

P-1196. Drug-Drug Interactions (DDIs) With Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis in Pediatric (Birth to &lt; 18 years of age) Hematopoietic Cell Transplant (HCT) Recipients

Open Forum Infectious Diseases2025-01-29

Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study

Clinical and Experimental Nephrology2024-04-133 citations

Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients

The Pediatric Infectious Disease Journal2024-01-1926 citations

2563. Cytomegalovirus (CMV) Prophylaxis with Letermovir (LET) in Pediatric (Birth to &lt; 18 years of age) Allogeneic Hematopoietic Cell Transplant (HCT) Recipients: Pharmacokinetics (PK), Safety and Efficacy Results of a Phase 2b study

Open Forum Infectious Diseases2023-11-274 citations

623. Preliminary Dosing for Adolescent Hematopoietic Stem-Cell Transplant (HSCT) Recipients Based on Pharmacokinetic (PK), Safety, and Efficacy Data of Letermovir (LET) for Cytomegalovirus (CMV) Prophylaxis

Open Forum Infectious Diseases2022-12-013 citations